295 related articles for article (PubMed ID: 29980467)
1. Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.
Mir H; Alhussein M; Alrashidi S; Alzayer H; Alshatti A; Valettas N; Mukherjee SD; Nair V; Leong DP
Can J Cardiol; 2018 Aug; 34(8):1059-1068. PubMed ID: 29980467
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors and cardiovascular toxicity.
Lyon AR; Yousaf N; Battisti NML; Moslehi J; Larkin J
Lancet Oncol; 2018 Sep; 19(9):e447-e458. PubMed ID: 30191849
[TBL] [Abstract][Full Text] [Related]
3. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy.
Brumbaugh AD; Narurkar R; Parikh K; Fanucchi M; Frishman WH
Cardiol Rev; 2019; 27(2):97-107. PubMed ID: 29912044
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicities associated with immune checkpoint inhibitors.
Yang S; Asnani A
Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of Immune Therapy.
Ganatra S; Parikh R; Neilan TG
Cardiol Clin; 2019 Nov; 37(4):385-397. PubMed ID: 31587780
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.
Asnani A
Curr Oncol Rep; 2018 Apr; 20(6):44. PubMed ID: 29644505
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Complications Associated With Novel Cancer Immunotherapies.
Jain V; Bahia J; Mohebtash M; Barac A
Curr Treat Options Cardiovasc Med; 2017 May; 19(5):36. PubMed ID: 28401456
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
Michel L; Totzeck M; Lehmann L; Finke D
Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
[TBL] [Abstract][Full Text] [Related]
15. Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall.
Piras L; Zuccanti M; Russo P; Riccio F; Agresti A; Lustri C; Dardani D; Ferrera A; Fiorentini V; Tocci G; Tini Melato G; Volpe M; Barbato E; Battistoni A
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473748
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity of immune checkpoint inhibitors: An updated review.
Behravesh S; Shomali N; Danbaran GR; Aslani S; Hemmatzadeh M; Hosseinzadeh R; Gowhari-Shabgah A; Mohammadi H
Biotechnol Appl Biochem; 2022 Feb; 69(1):61-69. PubMed ID: 33289168
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
18. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Waliany S; Lee D; Witteles RM; Neal JW; Nguyen P; Davis MM; Salem JE; Wu SM; Moslehi JJ; Zhu H
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():113-134. PubMed ID: 32776859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]